NCT00883675 - Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Docetaxel-Carboplatin

Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses

Trial Locations (12)

Dartmouth-Hitchcock Medical Center, Lebanon

Beijing Chaoyang Hospital, Beijing

Beijing Tumor Hospital, Beijing

Beijing Youyi Hospital, Beijing

China-Japan Friendship Hospital, Beijing

Xuanwu Hospital, Beijing

First Affiliated Hospital, Guangzhou Medical College, Guangzhou

Sun Yat-sen Cancer Center, Guangzhou

Shanghai Chest Hopsital, Pulmonary Medicine, Shanghai

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai

Shanghai Pulmonary Hospital, Shanghai

Tianjin Cancer Center, Tianjin